So let's look at the "rear view mirror." Stock dropped >50% is past 52 weeks. So let's look the "share prices valued on the future" -- so now the stock is consistently bouncing along the bottom at/near the 52 week low. That certainly tells you how investors view the future -- near the bottom.
Add the 200 million in stock dilution over the next 9 months that will be putting a lot downward pressure on share price. Half the stock has to be burned soon to payoff the creditors for the $120+ million debt. That leaves ~100 million shares to cover the $~10 million monthly cash burn. That takes until mid-2022 to be out of shares. Then what???
For upside -- so far mTNBC data, NASH data mTNBC BTD applications certainly hasn't helped the stock at all. So what will be coming? HIV BLA is already yesterday's newspaper, NASH data is pretty weak so far, Brazil is taking forever to even recruit... not going to be a pretty 1H 2020. Good luck with this "investment."
BP doesn't care about a self-destructive OTC penny stock rum by a CEO that attracts nothing but legal and regulatory actions. Pfizer cares about Merck, Gilead cares about ViiV, nobody cares about Cytodyn. Oh except for Vyera. Dream on.